文献速递肾癌与肾肿瘤

机器人辅助部分肾切除术治疗肾门与非肾门肾肿物:多中心前瞻性队列(NEPRAH研究,UroCCR 175)的围手术期、肿瘤学与功能结果比较

Robot-assisted Partial Nephrectomy for Hilar and Nonhilar Renal Masses: Comparison of Perioperative, Oncological, and Functional Results in a Multicentre Prospective Cohort (NEPRAH Study, UroCCR 175).
PubMed 文献 · Eur Urol Oncol · 2024-06-26

基于法国UroCCR前瞻性多中心队列2010至2023年29家医院3551例机器人辅助部分肾切除术(RAPN)患者,分析肾门肿瘤(RAPN-H,678例)与非肾门肿瘤(RAPN-NH,2773例)的结局。肾门组热缺血时间延长2.4分钟、手术时间延长11.4分钟、术后并发症风险升高(OR 1.33),但出血量、输血率、肾功能变化及三连胜达成率两组相当;中位随访31.9个月,无复发生存、癌症特异性生存和总生存均无显著差异。

要点

  • 肾门肿瘤RAPN的热缺血时间较非肾门延长2.4分钟,手术时间延长11.4分钟。
  • 肾门组术后并发症风险 OR 1.33(p=0.05),出血量、输血率及肾功能变化两组相当。
  • 中位随访31.9个月,肾门与非肾门组肿瘤学生存结局无显著差异。

核心结论

  • 患者和肿瘤特征而非仅肾门位置,应作为肾门肿瘤最佳手术策略的主要决定因素。

研究设计与样本

  • 观察性多中心队列研究,使用法国肾癌研究网络(UroCCR)前瞻性收集的数据。
  • 登记数据库纳入2010至2023年法国29家医院3551例接受RAPN的局限性或局部晚期肾肿物患者。
  • 分析人群3451例,其中2773例接受RAPN-NH,678例接受RAPN-H。
  • 比较两组围手术期、术后肾功能、肿瘤特征及生存,并比较三连胜(热缺血时间<25分钟、切缘阴性、无围手术期并发症)达成率,另对无血管阻断的RAPN进行亚组分析。
  • 采用单变量分析及多变量线性、逻辑回归和Cox比例风险模型(校正相关患者和肿瘤协变量)。

主要发现

  • 肾门组热缺血时间较长(β=2.4分钟;p<0.01),手术时间较长(β=11.4分钟;p<0.01),术后并发症风险较高(OR 1.33;p=0.05)。
  • 两组出血量、围手术期输血率、术后估算肾小球滤过率变化及三连胜达成率相当(p>0.05)。
  • 中位随访31.9个月,无复发生存(HR 0.82,95%CI 0.58-1.2;p=0.3)、癌症特异性生存(HR 1.1,95%CI 0.48-2.6;p=0.79)和总生存(HR 0.89,95%CI 0.52-1.53;p=0.69)均无显著差异。

关键数值与推荐

  • 三连胜定义为热缺血时间<25分钟、切缘阴性且无围手术期并发症。
  • 肾门组热缺血时间β=2.4分钟(p<0.01),手术时间β=11.4分钟(p<0.01),术后并发症OR 1.33(p=0.05)。
  • 无复发生存HR 0.82(95%CI 0.58-1.2;p=0.3),癌症特异性生存HR 1.1(95%CI 0.48-2.6;p=0.79),总生存HR 0.89(95%CI 0.52-1.53;p=0.69)。

临床怎么用

  • 原文未据此给出推荐;作者认为患者和肿瘤特征而非仅肾门位置应作为肾门肿瘤最佳手术策略的主要决定因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: A hilar location for a renal tumour is sometimes viewed as a limiting factor for safe partial nephrectomy. Our aim was to evaluate perioperative, oncological, and functional outcomes of robot-assisted partial nephrectomy (RAPN) for hilar tumours (RAPN-H) in comparison to RAPN for nonhilar tumours (RAPN-NH). METHODS: We conducted an observational, multicentre cohort study using prospectively collected data from the French Research Network on Kidney Cancer (UroCCR). The registry includes data for 3551 patients who underwent RAPN for localised or locally advanced renal masses between 2010 and 2023 in 29 hospitals in France. We studied the impact of a hilar location on surgery, postoperative renal function, tumour characteristics, and survival. We also compared rates of trifecta achievement (warm ischaemia time [WIT] <25 min, negative surgical margins, and no perioperative complications) between the groups. Finally, we performed a subgroup analysis of RAPN without vascular clamping. Variables were compared in univariable analysis and using multivariable linear, logistic, and Cox proportional-hazards models adjusted for relevant patient and tumour covariates. KEY FINDINGS AND LIMITATIONS: The analytical population included 3451 patients, of whom 2773 underwent RAPN-NH and 678 underwent RAPN-H. Longer WIT (β = 2.4 min; p < 0.01), longer operative time (β = 11.4 min; p < 0.01) and a higher risk of postoperative complications (odds ratio 1.33; p = 0.05) were observed in the hilar group. Blood loss, the perioperative transfusion rate, postoperative changes in the estimated glomerular filtration rate, and trifecta achievement rates were comparable between the groups (p > 0.05). At mean follow-up of 31.9 mo, there was no significant difference in recurrence-free survival (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.58-1.2; p = 0.3), cancer-specific survival (HR 1.1, 95% CI 0.48-2.6; p = 0.79), or overall survival (HR 0.89, 95% CI 0.52-1.53; p = 0.69). CONCLUSIONS AND CLINICAL IMPLICATIONS: Patient and tumour characteristics rather than just hilar location should be the main determinants of the optimal surgical strategy for hilar tumours. PATIENT SUMMARY: We found that kidney tumours located close to major kidney blood vessels led to a longer operation and a higher risk of complications during robot-assisted surgery to remove the tumour. However, tumours in these locations were not related to a higher risk of kidney function loss, cancer recurrence, or death.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sarkis J, Champy CM, Doumerc N, et al. Robot-assisted Partial Nephrectomy for Hilar and Nonhilar Renal Masses: Comparison of Perioperative, Oncological, and Functional Results in a Multicentre Prospective Cohort (NEPRAH Study, UroCCR 175). Eur Urol Oncol. 2024. PMID: 38937207. doi:10.1016/j.euo.2024.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。